Is the Pharmacokinetic Profile of a First Anti-TNF Predictive of the Clinical Outcome and Pharmacokinetics of a Second Anti-TNF?
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Is the Pharmacokinetic Profile of a First Anti-TNF Predictive of the Clinical Outcome and Pharmacokinetics of a Second Anti-TNF?
Authors
Keywords
-
Journal
INFLAMMATORY BOWEL DISEASES
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2018-04-26
DOI
10.1093/ibd/izy111
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases
- (2017) Niels Vande Casteele et al. GASTROENTEROLOGY
- American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
- (2017) Joseph D. Feuerstein et al. GASTROENTEROLOGY
- Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab
- (2016) B. Ungar et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease
- (2016) A. S. Strik et al. Expert Review of Clinical Pharmacology
- Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONICpost hocanalysis
- (2015) J.-F. Colombel et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management
- (2015) N. S. Ding et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Kinetics of Antibodies Against Adalimumab Are Not Associated With Poor Outcomes in IBD
- (2015) S Paul et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
- (2015) Niels Vande Casteele et al. GASTROENTEROLOGY
- Combination of C-reactive Protein, Infliximab Trough Levels, and Stable but Not Transient Antibodies to Infliximab Are Associated With Loss of Response to Infliximab in Inflammatory Bowel Disease
- (2015) X. Roblin et al. Journal of Crohns & Colitis
- Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases
- (2014) Xavier Roblin et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD
- (2014) Madeline Therese Frederiksen et al. INFLAMMATORY BOWEL DISEASES
- High-Dose Infliximab Therapy in Crohn's Disease: Clinical Experience, Safety, and Efficacy
- (2014) S. A. Hendler et al. Journal of Crohns & Colitis
- Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
- (2013) Xavier Roblin et al. Clinical Gastroenterology and Hepatology
- The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD
- (2012) S. Ben-Horin et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease
- (2012) Ingrid Ordás et al. Clinical Gastroenterology and Hepatology
- Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
- (2012) Shomron Ben–Horin et al. Clinical Gastroenterology and Hepatology
- Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
- (2011) Vincent Billioud et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease
- (2011) Jean-Frédéric Colombel et al. INFLAMMATORY BOWEL DISEASES
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
- (2010) Waqqas Afif et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
- (2010) A. Jamnitski et al. ANNALS OF THE RHEUMATIC DISEASES
- Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
- (2009) Javier P Gisbert et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
- (2009) G. M. Bartelds et al. ANNALS OF THE RHEUMATIC DISEASES
- Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies
- (2009) Klaus Bendtzen et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial
- (2008) Gert Van Assche et al. GASTROENTEROLOGY
- Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease
- (2007) Mark A. Ainsworth et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started